Has combined modality therapy improved the outlook in carcinoma of the esophagus?

Oncology (Williston Park). 1994 Sep;8(9):37-42; discussion 44-5, 50-2, 61.

Abstract

Carcinoma of the esophagus or the gastroesophageal junction is uncommon, accounting for approximately 1% of all malignancies in the United States. Approximately 11,000 new cases and 10,400 deaths are estimated in 1994. The diagnosis is often made late in Western countries, thus T3, T4, and N-positive lesions are encountered frequently. Nearly 50% of patients have advanced incurable disease at the time of diagnosis. Therefore, the prognosis of patients with carcinoma of the esophagus remains poor and the overall 5-year survival rates are still under 10%. The answer to the question in the title is yes, at least for some patients, on a short-term basis.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma / mortality
  • Adenocarcinoma / therapy*
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / therapy*
  • Combined Modality Therapy
  • Esophageal Neoplasms / mortality
  • Esophageal Neoplasms / therapy*
  • Humans
  • Neoplasm Staging
  • Palliative Care
  • Prognosis
  • Risk Factors
  • Survival Rate